These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 9062635)
1. Safety of Hymenoptera venom rush immunotherapy. Laurent J; Smiejan JM; Bloch-Morot E; Herman D Allergy; 1997 Jan; 52(1):94-6. PubMed ID: 9062635 [TBL] [Abstract][Full Text] [Related]
2. Rush hymenoptera venom immunotherapy is efficacious and safe. Pasaoglu G; Sin BA; Misirligil Z J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280 [TBL] [Abstract][Full Text] [Related]
3. [Safety of rush immunotherapy with Hymenoptera venom]. Sánchez-Morillas L; Reaño Martos M; Rodríguez Mosquera M; Iglesias Cadarso A; Domínguez Lázaro AR Allergol Immunopathol (Madr); 2005; 33(4):224-7. PubMed ID: 16045862 [TBL] [Abstract][Full Text] [Related]
4. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180 [TBL] [Abstract][Full Text] [Related]
5. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. Sturm G; Kränke B; Rudolph C; Aberer W J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961 [TBL] [Abstract][Full Text] [Related]
6. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom. Spoerl D; Bircher AJ; Scherer K J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719 [TBL] [Abstract][Full Text] [Related]
7. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. Fricker M; Helbling A; Schwartz L; Müller U J Allergy Clin Immunol; 1997 Jul; 100(1):11-5. PubMed ID: 9257781 [TBL] [Abstract][Full Text] [Related]
8. Development of new IgE specificities to hymenoptera allergens during venom-specific immunotherapy. Tavares B; Rordigues F; Pereira C; Loureiro G; Chieira C Eur Ann Allergy Clin Immunol; 2005 May; 37(5):171-6. PubMed ID: 15984315 [TBL] [Abstract][Full Text] [Related]
9. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155 [TBL] [Abstract][Full Text] [Related]
10. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191 [TBL] [Abstract][Full Text] [Related]
11. Ultrarush immunotherapy in patients with Hymenoptera venom allergy. Ruëff F; Przybilla B J Allergy Clin Immunol; 2001 May; 107(5):928-9. PubMed ID: 11344369 [No Abstract] [Full Text] [Related]
12. The sting challenge test in Hymenoptera venom allergy: pros and cons. Bilò MB; Brianzoni MF; Garritani MS; Antonicelli L; Farabollini B; Bonifazi F Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):377-81. PubMed ID: 14768522 [TBL] [Abstract][Full Text] [Related]
13. Near-fatal anaphylaxis after Hymenoptera venom immunotherapy. Wolf BL; Hamilton RG J Allergy Clin Immunol; 1998 Sep; 102(3):527-8. PubMed ID: 9768599 [No Abstract] [Full Text] [Related]
14. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. Müller U; Helbling A; Berchtold E J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583 [TBL] [Abstract][Full Text] [Related]
15. Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease. Engler RJ; Davis WS J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):556-9. PubMed ID: 8083461 [No Abstract] [Full Text] [Related]
16. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy. Gawlik R; Glück J; Jawor B; Rogala B Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651 [TBL] [Abstract][Full Text] [Related]
17. [Clinical and biological surveillance after the cessation of Hymenoptera venom desensitization]. Touraine F; Talayrach D; Florea O; Brianchon Ch; Preux PM; Bonnaud F Eur Ann Allergy Clin Immunol; 2003 Nov; 35(9):335-9. PubMed ID: 14716961 [TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy against hymenoptera venom: report of ten patients]. Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358 [TBL] [Abstract][Full Text] [Related]
19. Impact of Hymenoptera venom allergy and the effects of specific venom immunotherapy on mast cell metabolites in sensitized children. Cichocka-Jarosz E; Sanak M; Szczeklik A; Brzyski P; Pietrzyk JJ Ann Agric Environ Med; 2014; 21(2):294-301. PubMed ID: 24959779 [TBL] [Abstract][Full Text] [Related]
20. Systemic and local reactions of bee venom immunotherapy in Iran. Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]